Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niven Mehra

Showing results (51-60 of 161) with videos related to

Pageof 17
Sort By:
British Journal of Clinical Pharmacology|November 23, 2025
Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancerCatharina J P Op 't Hoog, Niven Mehra, Anouk van Kleef, et al.
European Urology Open Science|March 2, 2026
Discrepancies Between Global Consensus and Local Implementation in the Management of Advanced Prostate CancerNiven Mehra, Daniela E Oprea-Lager, Addy C M van de Luijtgaarden, et al.
Cancers|December 17, 2020
Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate CancerMinke Smits, Kamer Ekici, Samhita Pamidimarri Naga, et al.
European Urology Focus|December 12, 2025
Impact of Metastatic Hormone-sensitive Prostate Cancer Treatments on Health-related Quality of Life: A Systematic Review and Network Meta-analysisTessa van Elst, Pedro Lopez, Laurien M Buffart, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 4, 2021
Intra-therapeutic dosimetry of [<sup>177</sup>Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcomeSteffie M B Peters, Bastiaan M Privé, Maarten de Bakker, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 22, 2023
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studiesBastiaan M Privé, Mohamed A Boussihmad, Bart Timmermans, et al.
BMJ Open|December 1, 2021
Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocolJeroen H A Creemers, Inka Pawlitzky, Konstantina Grosios, et al.
EJNMMI Research|January 24, 2023
Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementationSteffie M B Peters, Maaike C T Mink, Bastiaan M Privé, et al.
British Journal of Cancer|December 16, 2021
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancerPeter H J Slootbeek, Iris S H Kloots, Minke Smits, et al.
Cancers|September 28, 2021
Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial CancerSandra van Wilpe, Victoria Wosika, Laura Ciarloni, et al.
Pageof 17

Showing results (51-60 of 161) with videos related to

Sort By:
Pageof 17
British Journal of Clinical Pharmacology|November 23, 2025
Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancerCatharina J P Op 't Hoog, Niven Mehra, Anouk van Kleef, et al.
European Urology Open Science|March 2, 2026
Discrepancies Between Global Consensus and Local Implementation in the Management of Advanced Prostate CancerNiven Mehra, Daniela E Oprea-Lager, Addy C M van de Luijtgaarden, et al.
Cancers|December 17, 2020
Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate CancerMinke Smits, Kamer Ekici, Samhita Pamidimarri Naga, et al.
European Urology Focus|December 12, 2025
Impact of Metastatic Hormone-sensitive Prostate Cancer Treatments on Health-related Quality of Life: A Systematic Review and Network Meta-analysisTessa van Elst, Pedro Lopez, Laurien M Buffart, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 4, 2021
Intra-therapeutic dosimetry of [<sup>177</sup>Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcomeSteffie M B Peters, Bastiaan M Privé, Maarten de Bakker, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 22, 2023
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studiesBastiaan M Privé, Mohamed A Boussihmad, Bart Timmermans, et al.
BMJ Open|December 1, 2021
Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocolJeroen H A Creemers, Inka Pawlitzky, Konstantina Grosios, et al.
EJNMMI Research|January 24, 2023
Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementationSteffie M B Peters, Maaike C T Mink, Bastiaan M Privé, et al.
British Journal of Cancer|December 16, 2021
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancerPeter H J Slootbeek, Iris S H Kloots, Minke Smits, et al.
Cancers|September 28, 2021
Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial CancerSandra van Wilpe, Victoria Wosika, Laura Ciarloni, et al.
Pageof 17